Quick Menu

Upcoming Journals

Cardiology and Angiology: An International Journal

Cardiology and Angiology: An International Journal, ISSN: 2347-520X,Vol.: 6, Issue.: 2


Dronedarone after Catheter Ablation of Atrial Fibrillation: A New Option in Hybrid Therapy


Felix Gramley1*, Felix Vogt2, Mohammed Natour1, Eva Koellensperger and Klaus Kettering4

1Heidelberg Private Clinic for Cardiology, Heidelberg, Germany.

2Department of Cardiology, RWTH Aachen University, Germany.

3Ethianum Heidelberg, Germany.

4Department of Cardiology, JW Goethe University, Frankfurt, Germany.


Article Information
(1) Francesco Pelliccia, Department of Heart and Great Vessels University La Sapienza, Rome, Italy.
(1) Marija M. Polovina, University Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.
(2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA.
(3) Shah Zeb, Lady Reading Hospital, Peshawar, Pakistan.
(4) Sam Said, Hospital Group Twente, Almelo, Hengelo, The Nethrelands.
(5) Guy-Armel Bounda, China Pharmaceutical University, China.
Complete Peer review History:




Background and Aim: Catheter ablation has become the therapy of choice in patients with symptomatic, recurrent, drug-refractory atrial fibrillation (AF). However, frequent AF recurrences often necessitate an adjunctive antiarrhythmic drug (AAD) therapy. Dronedarone is a new class III AAD with modest side effects. We compared a conventional AAD therapy (CAAT) with class I/III AADs to a novel therapy with dronedarone (NAAT)in regard to AF recurrences and improvement of symptoms.

Methodology: One hundred twenty five consecutive patients (84 men; mean age 62.1±12.4 years) with symptomatic paroxysmal (n=70) or persistent (n=55) drug refractory AF were enrolled in an open-label randomized study. Following successful pulmonary vein isolation (PVI) patients were randomized to receive CAAT (n=50), NAAT (n=50) or no AAD therapy (=control; n=25). Follow-up visits were scheduled at 3, 6, 9, and 12 months post ablation. Seven-day-Holter monitoring and patients’ histories served as indicators of treatment success. Bar signs of AF recurrence AADs were discontinued 6 months post ablation.

Results: The pre-ablation European Heart Rhythm Association (EHRA)-score decreased from 2.8±0.4 to 1.4±0.6 (NAAT) and 1.5±0.7 (CAAT) 6 months after PVI (1.7±0.7 in the control group). Fifty patients experienced an arrhythmia recurrence within 3 months. After 6 months, both hybrid therapy groups showed a significant advantage over the control group favoring sinus rhythm (SR).Whereas CAAT could retain its significant benefit at 9 months NAAT lost its relative advantages with only a positive trend remaining over the control group but a significant disadvantage compared to CAAT patients. At this point AF recurrences were found in 34% of NAAT patients, 26% of CAAT patients, and 40% of control patients. At 12 months, however, no group could preserve a significant lead over either of the others.

Conclusion: Dronedarone after PVI is safe and effective. Compared to a CAAT, NAAT reveals similar improvements of EHRA-scores and non-significantly different AF recurrence rates from 9 months on. Despite this, CAAT keeps significantly more patients in SR 9 months after PVI.


Keywords :

Atrial fibrillation; dronedarone; catheter; ablation.


Full Article - PDF    Page 1-10    Article Metrics


DOI : 10.9734/CA/2017/32001

Review History    Comments

Search this site

Advanced Search

Announcement & News

Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and its editors

We are happy to inform that Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and ...

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (...


  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2018, SCIENCEDOMAIN international. All rights reserved.